Patrick M. Moriarty
Impact in
- Surgery top 0.1%
- Lipoproteins and Cardiovascular Health
-
- Lipid metabolism and disorders
- Cardiac Valve Diseases and Treatments
Papers in
- Surgery 95
- Lipoproteins and Cardiovascular Health 93
-
- Lipid metabolism and disorders 10
- Co-authors
- Mary P. McGowan (4 shared papers)James M. Backes (22 shared papers)Cheryl Gibson (17 shared papers)Matthew K. Ito (3 shared papers)Christie Mitchell Ballantyne (10 shared papers)Lynne E. Maquat (3 shared papers)Janelle F. Ruisinger (14 shared papers)Seth J. Baum (8 shared papers)
- Journals
- Journal of clinical lipidology (28 papers)Atherosclerosis (12 papers)Journal of the American College of Cardiology (10 papers)The American Journal of Cardiology (8 papers)European Heart Journal (6 papers)
- Partner nations
- United StatesNetherlandsCanada
In The Last Decade
Patrick M. Moriarty
129 papers receiving 9.0k citations
Patrick M. Moriarty's Hit Papers
Peers
Comparison fields: 5 of 95
- Surgery 6.0k
- Cardiology and Cardiovascular Medicine 558
- Nutrition and Dietetics 238
- Endocrinology, Diabetes and Metabolism 119
- Molecular Biology 316
Countries citing papers authored by Patrick M. Moriarty
This map shows the geographic impact of Patrick M. Moriarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Moriarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Moriarty more than expected).
Fields of papers citing papers by Patrick M. Moriarty
This network shows the impact of papers produced by Patrick M. Moriarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Moriarty. The network helps show where Patrick M. Moriarty may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick M. Moriarty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 139 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement Hit paper breakdown → | 2022 | 924 |
| 2 | Lipoprotein(a) Reduction in Persons with Cardiovascular Disease Hit paper breakdown → | 2020 | 813 |
| 3 | Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients Hit paper breakdown → | 2023 | 635 |
| 4 | Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Hit paper breakdown → | 2011 | 536 |
| 5 | Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Hit paper breakdown → | 2011 | 453 |
| 6 | Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel Hit paper breakdown → | 2016 | 329 |
| 7 | Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel Hit paper breakdown → | 2015 | 322 |
| 8 | Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial Hit paper breakdown → | 2019 | 244 |
| 9 | The Role of Nutraceuticals in Statin Intolerant Patients Hit paper breakdown → | 2018 | 236 |
| 10 | Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a) Hit paper breakdown → | 2022 | 199 |
| 11 | 1998 | 191 | |
| 12 | 2016 | 185 | |
| 13 | 2019 | 170 | |
| 14 | Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial Hit paper breakdown → | 2020 | 170 |
| 15 | 2021 | 170 | |
| 16 | 2017 | 156 | |
| 17 | 2012 | 154 | |
| 18 | 2016 | 154 | |
| 19 | 2015 | 139 | |
| 20 | 2013 | 129 |
About Patrick M. Moriarty
Patrick M. Moriarty is a scholar working on Surgery, Cardiology and Cardiovascular Medicine, Nutrition and Dietetics, Pathology and Forensic Medicine and Ophthalmology, having authored 139 papers that have together received 9.5k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (93 papers), Lipid metabolism and disorders (10 papers), Blood properties and coagulation (3 papers), Selenium in Biological Systems (3 papers), Systemic Sclerosis and Related Diseases (2 papers), Inflammatory Biomarkers in Disease Prognosis (2 papers), Folate and B Vitamins Research (1 paper) and Nuts composition and effects (1 paper). The work is most often cited by research in Surgery (6.0k citations), Cardiology and Cardiovascular Medicine (558 citations), Nutrition and Dietetics (238 citations), Endocrinology, Diabetes and Metabolism (119 citations) and Molecular Biology (316 citations). Patrick M. Moriarty has collaborated with scholars based in United States, Netherlands and Canada. Frequent co-authors include Mary P. McGowan, James M. Backes, Cheryl Gibson, Matthew K. Ito, Christie Mitchell Ballantyne, Lynne E. Maquat, Janelle F. Ruisinger, Seth J. Baum, Paul Barton Duell and Daniel James Rader. Their work appears in journals such as Journal of clinical lipidology, Atherosclerosis, Journal of the American College of Cardiology, The American Journal of Cardiology and European Heart Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.